FDMT News and Press, 4D Molecular Therapeutics Inc. From 02/11/24

2024-02-11 04:27:27 ET Summary Ocular Therapeutix is using its Elutyx technology to develop drug candidates for eye disorders, with upcoming results from the HELIOS study for diabetic retinopathy Q2 2024. The company is also progressing with the phase 3 SOL study for wet age-relat...

2024-02-09 08:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-08 18:40:34 ET More on 4D Molecular Therapeutics 4D Molecular Therapeutics Advances Wet AMD Treatment Paradigm 4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024 4D Molecular Therapeutics up 3%, prices $300M equity Biggest sto...

2024-02-07 05:50:15 ET More on 4D Molecular Therapeutics 4D Molecular Therapeutics Advances Wet AMD Treatment Paradigm 4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024 4D Molecular stock jumps after positive interim data for eye disease dru...

2024-02-06 14:00:09 ET Kostas Biliouris from BMO Capital issued a price target of $70.00 for FDMT on 2024-02-06 14:05:00. The adjusted price target was set to $70.00. At the time of the announcement, FDMT was trading at $30.705. The overall price target consensus is at $...

A look at the top 10 most actives in the United States Phunware Inc. (PHUN) rose 19.9% to $0.41 on volume of 260,182,609 shares Palantir Technologies Inc. Class A (PLTR) fell 1.8% to $16.72 on volume of 167,698,349 shares PROSHARES TRUST (SQQQ) rose 0.5% to $11.78 on volume of 155,646,888...

2024-02-06 08:00:00 ET Summary 4D Molecular Therapeutics' gene therapy, 4D-150, shows potential to reduce the treatment burden for patients with severe wet AMD. Interim findings from a Phase 2 trial demonstrate up to an 89% reduction in yearly anti-VEGF injections with 4D-150. ...

2024-02-05 17:40:24 ET More on 4D Molecular Therapeutics 4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024 Seeking Alpha’s Quant Rating on 4D Molecular Therapeutics Read the full article on Seeking Alpha For further details se...

2024-02-05 16:08:07 ET More on 4D Molecular Therapeutics 4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024 4D Molecular stock jumps after positive interim data for eye disease drug Read the full article on Seeking Alpha For further d...

2024-02-05 13:05:53 ET More on Mid-day movers $ stocks. Karyopharm: Approaching The Bottom Ahead Of Earnings And Topline Data (Rating Upgrade) Karyopharm Therapeutics: Promising Potential With 3 Ongoing Phase 3 Studies But Risky Peraso Inc. (PRSO) Q3 2023 Earnings Ca...